Published on 05/12/2025

Storyboards: Closed System Transformations

Introduction to Closed System Transformations in Biologics and ATMPs

Closed systems and single-use systems are increasingly pivotal in the biopharmaceutical industry, especially in the context of advanced therapy medicinal products (ATMPs) and their validation processes. The regulatory landscape surrounding these technologies is complex, requiring a thorough understanding of aseptic controls, viral clearance validation, and the specific requirements outlined in guidelines such as ICH Q5A(R2).

This article serves as a comprehensive guide for pharmaceutical professionals seeking to navigate the critical aspects of closed system transformations, including the development of storyboards that effectively illustrate processes, risks, and controls necessary to adhere to Good Manufacturing Practices (cGMP) and achieve compliance with regulatory authorities such as the FDA, EMA, and MHRA.

Understanding Closed Systems and Their Importance

The definition of a closed system can vary, however, it generally refers to processes that minimize the risk of contamination between the external environment and the product. In biopharmaceutical manufacturing, this concept is crucial in maintaining the integrity and quality of the product throughout its lifecycle. Implementing closed systems helps reduce the risk of exposure to airborne contaminants, significantly enhancing the sterility of aseptic processing environments.

Closed systems can take many forms, including single-use technologies that facilitate the transportation, handling, and storage of products without compromising their safety or efficacy. The primary focus of these systems is on ensuring robust aseptic controls, as detailed in guidelines such as Annex 1 of the European Medicines Agency (EMA). These standards are crucial in reducing contamination risks while ensuring product quality and patient safety.

Key Components of Aseptic Controls in Closed Systems

Aseptic controls are a critical aspect of manufacturing biologics and ATMPs within closed systems. They encompass a wide array of practices, technologies, and planned procedures that aim to prevent contamination during the production process. Here are the key components essential for effective aseptic controls:

• Environmental Monitoring: Continuously monitor the manufacturing environment for viable and non-viable particles, including microbial contamination, to safeguard product integrity.
• Personnel Training: Ensuring that all personnel involved in the aseptic process are adequately trained in contamination control practices is critical.
• Equipment Qualification: All equipment used within closed systems should be thoroughly calibrated and validated to ensure reliability during operation.
• Process Validation: Validate all processes involved within closed systems to confirm that they consistently produce a product meeting predetermined specifications. This is typically part of FDA process validation requirements.

Incorporating these aseptic controls into closed system transformations is vital for reducing contamination risks and improving the overall safety of ATMPs. It is also important to consider the nuances of potency identity and critical quality attributes (CQAs) that directly influence the success of these processes.

Viral Clearance Validation: A Necessary Consideration

Viral clearance validation is essential in ensuring the safety of biologics by confirming that any potential viral contaminants are eliminated or inactivated during the manufacturing process. In the context of closed systems, the incorporation of robust viral clearance strategies must be part of the overall validation process.

The validation process typically comprises several elements, including but not limited to:

• Spiking Studies: These studies involve introducing a known quantity of virus into the process to demonstrate that the manufacturing system can effectively reduce viral loads to acceptable levels. This serves as a critical component in demonstrating the efficacy of viral clearance methods.
• Process Parameters Optimization: Identifying and optimizing process parameters that contribute to viral clearance is crucial, especially under closed system conditions where interactions are more constrained.
• Recovery Studies: Quantifying the recovery of both the biologic product and the viral clearance agents is critical to assess process efficiency and continuity.

Organizations must tailor their validation processes to consider the unique challenges posed by ATMPs, which may have different viral safety requirements compared to conventional biologics. This requires close adherence to regulatory guidelines and a systematic approach to validation that encompasses both the characterization of the product and the assessment of critical process parameters (CPPs).

Implementing Spiking Studies for Effective Validation

Spiking studies are an integral part of viral clearance validation and require meticulous planning and execution. This section will elaborate on the step-by-step methodology for conducting spiking studies within closed systems aimed at fulfilling regulatory expectations.

Step 1: Define Study Objectives

The first step in any spiking study is to clearly define the objectives. This involves:

• Determining the specific viruses to be used for spiking based on risk assessment and product type.
• Establishing the acceptable limits for viral loads that will guide the study design.
• Outlining how results will be assessed in terms of their impact on product quality and safety.

Step 2: Selecting Appropriate Models

The next step involves selecting appropriate experimental models that closely mimic production processes. Considerations include:

• Simulating the physicochemical environment of the closed system.
• Using representative materials and equipment that reflect the actual manufacturing setup.

Step 3: Conducting the Spiking Study

Once the model has been established, the spiking study can commence. Important aspects to consider during this phase include:

• Careful control of the spiking concentration to ensure that it is consistent with the defined objectives.
• Monitoring all process parameters closely to capture any deviations that may affect the outcome.
• Documenting all observations thoroughly for subsequent analysis and reporting.

Step 4: Analyzing Results

Post-study analysis is crucial for interpreting data and assessing the effectiveness of viral clearance within the closed system. Analysis should focus on:

• Evaluating the reduction of spiked virus levels compared to baseline measurements.
• Identifying any variables that may have affected viral clearance and strategies to mitigate such issues in future runs.
• Documenting the findings in a comprehensive report that aligns with regulatory expectations.

Step 5: Conclusion and Recommendations

The final step involves synthesizing the insights gained from the spiking studies to propose any necessary improvements to the process, focusing on enhancing both the effectiveness of viral clearance and the overall quality of the product. This reinforces the iterative nature of process validation, emphasizing the need for continuous improvement aligned with both cGMP practices and regulatory standards.

Chain of Identity and Custody in Closed Systems

Establishing a secure chain of identity and custody (COI/COC) is vital to maintaining the integrity of the product throughout its lifecycle. This applies particularly to closed systems where the physical handling and transfer of materials are minimized.

Key components of maintaining a secure COI/COC include:

• Documentation: Accurate tracking and documentation at each stage of the process to ensure traceability and accountability. This includes batch records, material logs, and inventory management systems.
• Electronic Systems: Utilizing electronic tracking systems for real-time monitoring of materials. These systems should be validated to ensure their reliability and security.
• Training: Regular training programs for personnel to ensure consistent compliance with COI/COC procedures.

PPQ and CPV Tailoring for ATMPs

Process Performance Qualification (PPQ) and Continued Process Verification (CPV) are critical in ensuring that a closed systems process remains within its validated state throughout its operational lifecycle.

In the context of ATMPs, the tailoring of these programs requires a unique approach that considers the individual characteristics of each product while complying with regulatory expectations. Key steps include:

• Understanding Product-Specific Properties: Tailoring PPQ and CPV strategies to reflect the unique properties of the ATMP, such as the genetic makeup or biologics characteristics.
• Risk Assessment: Conducting risk assessments to identify critical points where failures could occur and implementing controls to mitigate those risks.
• Longitudinal Studies: Establishing methods for ongoing evaluation of the process, ensuring that it remains within the specified limits over time.

These tailored approaches provide assurances that ongoing production of ATMPs will meet strict regulatory standards while safeguarding patient safety and product efficacy.

Conclusion: Navigating the Future of Closed System Transformations

As the biopharmaceutical industry shifts towards more complex biologics and ATMPs, closed system transformations will play a pivotal role in ensuring regulatory compliance and product safety. The integration of robust aseptic controls, thorough viral clearance validation processes, meticulous spiking studies, and secure chains of identity and custody are essential components of this transformation.

Continuous improvement through the adaptation of PPQ and CPV processes tailored for ATMPs will ensure that companies remain compliant with evolving regulatory demands set forth by authorities like the FDA and EMA. As such, staying informed about industry trends, regulatory updates, and technological advancements is vital for professionals in the field.

By following the methodologies outlined in this tutorial, biopharmaceutical companies can enhance their understanding and implementation of closed systems, ultimately ensuring safe, effective, and compliant production of biologics and ATMPs.